Skip to content

Clinical trials

Neuroinflammatory Diseases trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Neuroinflammatory Diseases Country / region: United States Clear all

58 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20051
20072
20081
20111
20121
20132
20153
20163
20172
20184
20192
20205
20213
20223
20237
20244
20253
202611

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed22
Recruiting16
Terminated7
Active, not recruiting3
Not yet recruiting3
Unknown status3
Enrolling by invitation2
Withdrawn1
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Mental Health (NIMH)9
Brain Inflammation Collaborative2
National Institute of Neurological Disorders and Stroke (NINDS)2
Penn State University2
Stony Brook University2
University of Alabama at Birmingham2
VA Office of Research and Development2
Aaron Ritter, MD1
Biomed Industries, Inc.1
Boston University Charles River Campus1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Neuroinflammatory Diseases58
Alzheimer Disease7
Multiple Sclerosis7
Inflammation6
Brain Injuries, Traumatic5
Cognitive Dysfunction5
Chronic Pain4
Major Depressive Disorder4
Anxiety Disorders3
Brain Diseases3

Trials

Showing 1 to 25 of 58. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.